RA Capital Management Discloses 24.1% Stake in SpyGlass Pharma Following IPO

summarizeSummary

RA Capital Management and its affiliates, including director Peter Kolchinsky, reported a substantial 24.1% beneficial ownership in SpyGlass Pharma, Inc. following the company's initial public offering.

check_boxKey Events

• Major Institutional Ownership

  RA Capital Management and its affiliates reported a 24.1% beneficial ownership in SpyGlass Pharma, holding 8,022,639 shares.

• Significant Investment Post-IPO

  The investment group acquired shares through pre-IPO preferred stock conversions and a $59 million purchase from underwriters at the IPO price of $16.00 per share, totaling over $100 million in aggregate investment.

• Director Representation

  Dr. Zachary Scheiner, a Principal of RA Capital, serves as a director on SpyGlass Pharma's board, aligning the investor's interests with company governance.

• Investment Intent

  The shares were acquired for investment purposes, with no current intent to change control, though future acquisitions or dispositions may occur based on market conditions and company prospects.

auto_awesomeAnalysis

This Schedule 13D filing provides comprehensive details on the significant stake acquired by RA Capital Management and its affiliated funds in SpyGlass Pharma. The disclosure of a 24.1% beneficial ownership, valued at approximately $222 million based on today's stock price, signals strong institutional confidence in the newly public company. This follows a Form 4 filing on February 11, 2026, which indicated RA Capital's increased stake, and this 13D now provides the full scope of their holdings and investment intent. The involvement of a RA Capital principal, Dr. Zachary Scheiner, as a director further aligns the investor's interests with the company's strategic direction. The filing also outlines lock-up agreements and investors' rights, common for IPO-related investments, which govern future share dispositions and registration rights.